


Amendment to the Abstract:

After the claims, please insert the Abstract on the following page. The Abstract is the same as that published in the priority document PCT WO 02/062830 A2 (International Application No. PCT/EP02/01181).

-- ABSTRACT



(I)

The invention relates to the use of specific tripeptides for the treatment of neurodegenerative diseases. The tripeptide derivatives satisfy the following formula (I): wherein X represents OH, (C₁₋₅)alkoxy, NH₂, NH-C₁₋₅-alkyl, N(C₁₋₅ alkyl)₂; R₁ is a residue derived from any of the amino acids Phe, Tyr, Trp, Pro, each of which may optionally be substituted by a (C₁₋₅) alkoxy group, a (C₁₋₅) alkyl group or a halogen atom, and Ala, Val, Leu, or Ile; R₂ is a residue which is derived from any of the amino acids Gly, Ala, Ile, Val, Ser, Thr, His, Arg, Lys, Pro, Glu, Gln, pGlu, Asp, Leu and Asn; R₃ and R₄ independently represent H, OH, (C₁₋₅)alkyl, or (C₁₋₅)alkoxy, provided that R₃ and R₄ are not both OH or (C₁₋₅)alkoxy; R₅ represents H, OH, (C₁₋₅)alkyl or (C₁₋₅)alkoxy; and wherein R₀ preferably represents a cinnamoyl residue; or pharmaceutically acceptable salts thereof. --